BR112023022584A2 - Variante fc com afinidade intensificada com receptores fc e estabilidade térmica melhorada - Google Patents
Variante fc com afinidade intensificada com receptores fc e estabilidade térmica melhoradaInfo
- Publication number
- BR112023022584A2 BR112023022584A2 BR112023022584A BR112023022584A BR112023022584A2 BR 112023022584 A2 BR112023022584 A2 BR 112023022584A2 BR 112023022584 A BR112023022584 A BR 112023022584A BR 112023022584 A BR112023022584 A BR 112023022584A BR 112023022584 A2 BR112023022584 A2 BR 112023022584A2
- Authority
- BR
- Brazil
- Prior art keywords
- domain variants
- receptors
- variant
- thermal stability
- improved thermal
- Prior art date
Links
- 102000009109 Fc receptors Human genes 0.000 title abstract 2
- 108010087819 Fc receptors Proteins 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
variante fc com afinidade intensificada com receptores fc e estabilidade térmica melhorada. a presente invenção refere-se a variantes do domínio fc, incluindo variantes do domínio fc com função efetora competente. a presente invenção também fornece ácidos nucleicos que codificam variantes do domínio fc e células hospedeiras para fazer variantes do domínio fc. também são fornecidos métodos para aumentar o rendimento de variantes do domínio fc e métodos de uso das variantes de domínio fc para tratar uma doença.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163193665P | 2021-05-27 | 2021-05-27 | |
EP21315127 | 2021-07-15 | ||
PCT/IB2022/055019 WO2022249146A1 (en) | 2021-05-27 | 2022-05-27 | Fc VARIANT WITH ENHANCED AFFINITY TO Fc RECEPTORS AND IMPROVED THERMAL STABILITY |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023022584A2 true BR112023022584A2 (pt) | 2024-01-09 |
Family
ID=82358573
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023022584A BR112023022584A2 (pt) | 2021-05-27 | 2022-05-27 | Variante fc com afinidade intensificada com receptores fc e estabilidade térmica melhorada |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230077531A1 (pt) |
EP (1) | EP4347640A1 (pt) |
KR (1) | KR20240015093A (pt) |
AU (1) | AU2022282666A1 (pt) |
BR (1) | BR112023022584A2 (pt) |
CA (1) | CA3216005A1 (pt) |
CO (1) | CO2023016432A2 (pt) |
IL (1) | IL308733A (pt) |
TW (1) | TW202306584A (pt) |
WO (1) | WO2022249146A1 (pt) |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0627932B1 (en) | 1992-11-04 | 2002-05-08 | City Of Hope | Antibody construct |
WO1997014719A1 (en) | 1995-10-16 | 1997-04-24 | Unilever N.V. | A bifunctional or bivalent antibody fragment analogue |
GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
WO2002002781A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
US20090010920A1 (en) * | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
TWI803876B (zh) | 2011-03-28 | 2023-06-01 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
CA2871934C (en) * | 2012-04-30 | 2023-06-13 | Medimmune, Llc | Molecules with reduced effector function and extended half-lives, compositions, and uses thereof |
US9580486B2 (en) | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
AU2016210068B2 (en) | 2015-01-23 | 2021-10-28 | Sanofi | Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123 |
KR20180101623A (ko) * | 2016-02-03 | 2018-09-12 | 암젠 리서치 (뮌헨) 게엠베하 | Psma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물 |
PT3443006T (pt) | 2017-03-17 | 2023-10-26 | Sanofi Sa | Proteínas de ligação triespecíficas e/ou trivalentes |
AU2019212638A1 (en) | 2018-01-26 | 2020-09-17 | Genzyme Corporation | Fc variants with enhanced binding to FcRn and prolonged half-life |
WO2019185164A1 (en) * | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
-
2022
- 2022-05-27 BR BR112023022584A patent/BR112023022584A2/pt unknown
- 2022-05-27 US US17/826,295 patent/US20230077531A1/en active Pending
- 2022-05-27 KR KR1020237044602A patent/KR20240015093A/ko unknown
- 2022-05-27 IL IL308733A patent/IL308733A/en unknown
- 2022-05-27 WO PCT/IB2022/055019 patent/WO2022249146A1/en active Application Filing
- 2022-05-27 TW TW111119900A patent/TW202306584A/zh unknown
- 2022-05-27 CA CA3216005A patent/CA3216005A1/en active Pending
- 2022-05-27 EP EP22726534.5A patent/EP4347640A1/en active Pending
- 2022-05-27 AU AU2022282666A patent/AU2022282666A1/en active Pending
-
2023
- 2023-11-29 CO CONC2023/0016432A patent/CO2023016432A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2022249146A1 (en) | 2022-12-01 |
CA3216005A1 (en) | 2022-12-01 |
US20230077531A1 (en) | 2023-03-16 |
IL308733A (en) | 2024-01-01 |
CO2023016432A2 (es) | 2023-12-11 |
EP4347640A1 (en) | 2024-04-10 |
KR20240015093A (ko) | 2024-02-02 |
AU2022282666A1 (en) | 2024-01-18 |
TW202306584A (zh) | 2023-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR121761A2 (es) | Polipéptidos que presentan actividad de fosfolipasa y polinucleótidos que codifican los mismos | |
BRPI1008692B8 (pt) | anticorpo antagonista tendo especificidade para ox40 humano, sequência de dna isolado, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção do referido anticorpo, composição farmacêutica, uso do 5 referido anticorpo e proteína de fusão | |
BRPI0717768B8 (pt) | anticorpo, epítopo, sequência de dna isolada, vetor de clonagem ou expressão, processo para a produção do anticorpo, composição farmacêutica, e, uso de um anticorpo | |
CR20120086A (es) | Anticuerpos humanos de alta afinidad para la angiopoyetina-2 humana | |
BR112018011073A2 (pt) | anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização | |
BR112021005769A2 (pt) | proteínas de ligação a dll3 e métodos de uso | |
BR112018072946A2 (pt) | proteínas de fusão a gdf15 e usos das mesmas | |
EA201890169A1 (ru) | Тау-связывающие антитела | |
BRPI0817154B8 (pt) | "método de modificar uma célula de levedura para a produção de etanol, célula de levedura modificada, uso de uma célula de levedura modificada e método para a produção de etanol" | |
BRPI0713000A8 (pt) | Proteína de ligação multiespecífica de cadeia simples, composição farmacêutica e uso da referida proteína de ligação multiespecífica de cadeia simples | |
BRPI0619595A8 (pt) | anticorpo neutralizante, epítopo, seqüência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção de um anticorpo, composição farmacêutica, e, uso de um anticorpo neutralizante humanizado ou completamente humano | |
CY1110860T1 (el) | Αναστροφη μεταγραφαση τελομερασης πτηνου | |
BR112014015851A2 (pt) | proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17 | |
ECSP088262A (es) | Proteínas de fusión de albúmina | |
BR112013032764A2 (pt) | misturador estático para tratamento de gases de exaustão e método de fabricação do mesmo | |
BR112012011305A2 (pt) | uso de uma proteína homóloga a uma proteína meab para aumentar a atividade enzimática de uma mutase do ácido 3-hidroxicarboxílico-coa | |
BRPI0509168A (pt) | xilanases modificadas que exibem expressão melhorada | |
BRPI0821034A8 (pt) | Vírus influenza b recombinante, seu uso, metodo de preparação, composição de vacina o contendo e seu gene m, bem como ácido nucléico isolado, molécula do vírus influenza m e seu uso e método para aumentar a taxa de crescimento de vírus influenza b deficiente de replicação | |
BR112015001892A2 (pt) | cocleados feitos com fosfatidilserina de soja | |
BRPI0801078A2 (pt) | processo para relaxar ou alisar os cabelos | |
BR112021023048A2 (pt) | Moléculas de ligação a cd19 e usos das mesmas | |
AR067830A1 (es) | Proteinas streptococcus inmunogenicas | |
BR112015019729A2 (pt) | composição inibidora da il-1b e uso da mesma | |
BRPI0516773A (pt) | enzima lacase e uso da mesma | |
BR112019013007A2 (pt) | organismo microbiano não natural, método de produção de um composto bioderivado, composto bioderivado e composição |